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Editor’s key points
† Propofol-induced changes in
mid-latency auditory-evoked
potentials (MLAEPs) have
not been well described in
children.
† The authors recorded
MLAEPs during the awake
state and at three different
propofol target
concentrations.
† Dose-dependent changes in
MLAEP latencies and
amplitudes were found.
† MLAEP-based analyses may
be suitable for depth of
anaesthesia monitoring
during propofol anaesthesia
in children.
Background. Propofol is increasingly used in paediatric anaesthesia, but can be
challenging to titrate accurately in this group. Mid-latency auditory-evoked potentials
(MLAEPs) can be used to help titrate propofol. However, the effects of propofol on
MLAEP in children are unclear. Therefore, we investigated the relationship between
propofol and MLAEP in children undergoing anaesthesia.
Methods. Fourteen healthy children aged 4–16 yr received anaesthesia for elective
surgery. Before surgery, propofol was administered in three concentrations (3, 6, 9 mg
ml21) through a target-controlled infusion pump using Kataria and colleagues’ model.
MLAEPs were recorded 5 min after having reached each target propofol concentration
at each respective concentration. Additionally, venous propofol blood concentrations
were assayed at each measuring time point.
Results. Propofol increased all four MLAEP peak latencies (peaks Na, Pa, Nb, P1) in a
dose-dependent manner. In addition, the differences in amplitudes were significantly
smaller with increasing propofol target concentrations. The measured propofol plasma
concentrations correlated positively with the latencies of the peaks Na, Pa, and Nb.
Conclusions. Propofol affects MLAEP latencies and amplitudes in children in a dose-
dependent manner. MLAEP measurement might therefore be a useful tool for
monitoring depth of propofol anaesthesia in children.
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Although volatile anaesthetics are the most frequently used
hypnotic medication in paediatric anaesthesia, the i.v. drug
propofol is becoming increasingly popular. The advantages
and disadvantages associated with the use of propofol in
paediatric anaesthesia were recently highlighted by Lerman
and Jo¨hr.1 Although volatile anaesthetics are simple to ad-
minister, they are associated with a high rate of emergence
agitation in children.2 – 4 In contrast, recovery of paediatric
patients after propofol anaesthesia is seldom associated
with emergence agitation.5 A further advantage of propofol
is the reduced frequency of postoperative nausea and vomit-
ing.6 However, one of the major challenges associated with
the use of propofol is the limited ability to continuously
measure propofol concentrations in patients,7 in contrast to
the simple and effective end-tidal measurement of volatile
anaesthetics. EEG-based monitors can be used to estimate
the effect of propofol on brain cortical activity. Measurement
of mid-latency auditory-evoked potentials (MLAEPs) is
another method used to assess the effect of propofol on
the brain activity.8 In contrast with adults, the influence of
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propofol on MLAEP in children is not well described. There-
fore, the aim of this study was to investigate the alterations
in raw MLAEPs during anaesthesia with propofol and to
examine potential dose–response relationships between
three propofol target concentrations, measured propofol
concentrations, and MLAEP parameters.
Methods
Patients and study design
Study approval was obtained by our institutional review
board (Project-Nr. 148/00, University of Munich, Munich,
Germany) and written informed consent was signed either
by the child and their parents or by the parents alone.
In total, 14 patients aged 4–16 yr were enrolled in the
study (Table 1). All patients were undergoing elective lower
limb orthopaedic surgery. Patients classified ASA I or II
were selected for this study. Exclusion criteria were a
history of neurological or hearing disorders, the intake of
centrally acting substances, or neurological diseases.
MLAEP acquisition
MLAEP measurement was performed as follows (see also
Daunderer and colleagues).8 For the measurement of
auditory-evoked potentials (AEPs), the skin was cleaned
with acetone before the attachment of Ag/AgCl adhesive
electrodes (Neuroline 7200 00-S, Ambu/Medicotest,
Denmark) on A1, A2, Fp1, Fp2, Fpz, and Cz according to the
international 10/20 system. Adjustable headphones were
then applied and the correct placement was visually con-
trolled. For accurate data acquisition, inter-electrode impe-
dances were kept below 5 kOhm. The electrodes were
connected to a preamplifier (POD, Siemens Medical, Erlan-
gen, Germany) wired to feed four recording channels
(A1/Fp1, A2/Fp2, A1/Cz, and A2/Cz with Fpz as the common
ground). Amplification and digitalization of the signals oc-
curred within the preamplifier (sensitivity 0.017 mV, sam-
pling rate 4 kHz). Signals were transmitted to the recording
system via broadband fibreglass cables. Measured data
were analysed in an offline analysis with specially
designed software (NaMo v. 8.0, Toennies/Viasys, Hoechberg,
Germany). Extraction of 1000 successive EEG epochs of 100
ms duration after each stimulus was done. Out of the 1000
EEG epochs, one single high-quality AEP for each channel
was averaged. The time taken to obtain one AEP measure-
ment was 108 s. EEG epochs with amplitudes above the
cutting point of 250 mV were rejected and not added to the
AEP. No other additional data filtering was done. As a conse-
quence of the online rejection, when values were above the
cutting point, only an approximate time for one AEP collec-
tion can be given—in this study, it was an average time of
108 s. AEP signals were manually inspected and the
channel with the best recordings was selected. For quality
control, two independent investigators (M.F., G.F.) performed
the visual data analysis. These investigators were aware of
the recordings but blinded to individual patient data (age,
body weight) and clinical data (propofol target concentra-
tions, state of consciousness). Signal quality was classified
as excellent, acceptable, or insufficient for interpretation.
Distorted or insufficient AEP signals were excluded from
further analysis. MLAEP peaks were identified according to
the nomenclature of Picton and colleagues.9 Negative
peaks were manually marked by the two investigators with
Na and Nb, whereas positive peaks of the MLAEP were
marked as Pa and P1. In addition, the differences of inter-
peak amplitudes Na/Pa, Pa/Nb, and Nb/P1 were measured
and calculated. Adequate AEP detection was validated by
identification of the brainstem AEP peak V (data not shown).
Anaesthetic regime
After the patients’ arrival at the operating theatre, standard
clinical monitoring (including ECG, pulse oximetry, oscillo-
metric arterial pressure monitoring) was applied. An i.v. line
was inserted into a forearm vein. After placement of the
above-described MLAEP unit, a first AEP recording was
taken in the premedicated awake state. Patients were
advised to keep their eyes open and fixate on one point.
Anaesthesia was induced by the application of propofol
using a target-controlled infusion (TCI) pump (Alaris, Ho¨ch-
berg, Germany). This TCI pump was based on the pharmaco-
kinetic model of Kataria and colleagues,10 consisting of a
weight-proportional model in which age is an additional
covariate for the rapid distribution compartment (V2).
Anaesthesia was induced using a target concentration (Ct)
of propofol of 6 mg ml21. Before tracheal intubation, a single
i.v. dose of 0.4 mg kg21 atracurium was administered. After
intubation, the Ct was raised to 9 mg ml
21. A second i.v.
line was inserted in an extremity different from the one
into which the propofol was being infused. After reaching
the target concentration, steady state was kept for an
extra 5 min. Thereafter, the MLAEP of the respective target
concentration was recorded and documented into the
study computer. Subsequently, the second concentration
(Ct of 3 mg ml
21) was programmed into the TCI pump.
After achieving this target propofol concentration, 5 min
was left to pass until taking the MLAEP reading. The same
Table 1 Patient characteristic data; data are presented as mean
(SD) (range)
Patient characteristic data Mean (SD) (range)
Patient characteristics
Number of patients (n) 14
Age (yr) 8.6 (4.3) (4.0–16.5)
Weight (kg) 29.2 (14.6) (15.0–60.0)
Height (cm) 125.9 (26.2) (67.0–160.0)
Gender: male/female (n) 6/8
Details of anaesthetic procedure
Duration of anaesthesia (min) 171.4 (52.0) (78.0–253.0)
Premedication
Dosage midazolam (mg kg21) p.o. 0.42 (0.14)
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procedure was done for the third target concentration of
6 mg ml21. After the propofol titration and MLAEP recording,
and before surgical manipulation, all patients received 0.3 mg
kg21 sufentanil. Further anaesthetic management was based
on the anaesthetic standard for surgical procedures. The an-
aesthetist was blinded to the AEP monitoring and recording.
Modified AEP index
Reviewing the literature, MLAEPs are often indexed to sim-
plify their applicability. We applied therefore a modified
index according to the work of Mantzaridis and Kenny11 12
to our data. For calculation of this index, all amplitude read-
ings were multiplied by 100. We then summed the square
roots of the absolute difference in the amplitude of every
two consecutive peaks observed between 10 and 100 ms.
This results in a single index number.
Determination of plasma propofol concentration
At the end of every MLAEP observation, a venous blood
sample was drawn from the second i.v. line. Venous whole
blood samples were stored at 2608C until further analysis.
Propofol measurement was done by liquid chromatography
ion spray tandem mass spectrometry according to the
method described by Beaudry and colleagues.13
Statistical analysis
Comparisons were performed for the modified AEP index,
peak latencies, and differences in peak amplitudes between
the awake state and the three propofol concentrations (‘con-
sciousness states’) using the Page test for comparison of four
and three samples (out of four propofol levels, i.e. three pro-
pofol concentrations and baseline without propofol) ordered
by concentration followed by pairwise comparisons with the
Wilcoxon signed-rank test. Exploring potential endpoints for
monitoring different states in anaesthesia, closed testing
accounts for multiple comparisons of groups at a two-sided
0.05 level of significance. However, the 0.05 level was not
further adjusted for testing of the multiple endpoints.
Propofol whole blood concentrations and selected peak
MLAEP were calculated in a non-linear regression and
applied to a dose–response curve. The data were fitted to
the commonly used Emax model: Effect¼E0+(Emax2E0)×Cplg /
(Cpl50
g +Cplg ), where ‘Effect’ reflects the drug response, Cpl the
measured propofol plasma concentration, Cpl50 the propofol
concentration associated with 50% of the maximal drug
effect, E0 the baseline effect, corresponding to the response,
when the dose of the drug is zero, Emax the maximal effect
on MLAEP, which can be achieved by propofol, and g the Hill
coefficient of the dose–response curve.
Data are presented as mean (SD). Statistical calculations
were performed using Sigma Plot 11.0, Chicago, IL, USA, Stat-
Xact of Cytel Studio 6.2.0, CytelCorporation, Cambridge, MA,
USA, and R 2.14, www.r-project.org.
Results
General patient characteristic data and details of anaesthe-
sia are presented in Table 1.
MLAEPs were recorded from 14 individuals at each time
point, resulting in 56 MLAEPs in total. The data quality was
rated excellent in 39 AEPs and good in 17 AEPs. None of
the MLAEPs was excluded.
All four peak latencies of the MLAEPs increased with higher
propofol target concentrations (Ct) (Fig. 1). For the peak Pa, all
measurements were different from the premedicated awake
state, including at the lowest infusion target (3 mg ml21). Dif-
ferences were also seen between the different propofol
target concentrations in each MLAEP peak. In most of the
cases, the increase in peak latencies reached the level of stat-
istical significance (Fig. 1). In the majority of patients, the P1
latency reached the upper measuring limit of 100 ms at propo-
fol target concentrations of 6 and 9 mg ml21. In these cases,
latency values were set at 100 ms. Similar results could be
found for the peak latency Nb at the highest target propofol
concentration (9 mg ml21) (Fig. 2).
MLAEP peak latencies were not the only signals to be
altered under the influence of propofol. Differences of the
corresponding amplitudes decreased with increasing propo-
fol concentrations (Fig. 3). This was statistically significant
for differences of amplitudes for Na/Pa and Pa/Nb in compari-
son with the awake state (Fig. 3). As described above, for
the two highest propofol concentrations, the difference Nb
and P1 were frequently outside the measuring window of
100 ms. This fact creates border effects for Nb/P1. Therefore,
the validity of the difference in amplitudes of Nb/P1 is
limited.
In general, the correlation between peak latencies and
differences in amplitudes and the propofol target concentra-
tions is variable. For example, Pa shows less change at the
3 mg ml21 level compared with strong alteration at TCI
levels of 6 and 9 mg ml21. In contrast, larger changes can
be seen for the peak latency Nb at TCI 3 mg ml21.
Changes in inter-peak amplitudes also demonstrate
differences. Strong changes can be seen for Na/Pa at TCI
3 mg ml21 but hardly any at the same level for Nb/P1. This
is also associated with the border effects of the measuring
window of 100 ms of latency.
In 10 out of the 14 study persons, a second i.v. line could be
established for blood sampling for venous propofol concen-
tration determination. In four patients, no second i.v. line
could be inserted or blood could not be aspirated from the
i.v. line. A total of 40 venous blood samples for propofol ana-
lysis were collected in these patients. Linear regression
between TCI target concentration and measured propofol
plasma concentration showed r¼0.704 (P,0.001, n¼40).
When propofol blood concentrations were plotted against
peak latencies Na, Pa, Nb, and P1, a non-linear increase in la-
tencies was observed (Fig. 4). Differences in amplitudes
showed a non-linear decrease with higher propofol concen-
trations (Fig. 5). The results of fitting to the Emax model are
shown in Table 2.
The calculated modified AEP index decreased with in-
creasing propofol concentrations in all individuals. The level
of statistical significance was reached between all different
‘consciousness states’. The MLAEP index showed a non-linear
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decrease with higher measured propofol plasma concentra-
tions (Fig. 6).
Discussion
Our main finding is that propofol infusion alters raw MLAEPs
in children, and that these changes occur in a dose-
dependent manner. Propofol increases peak latencies Na,
Pa, Nb, and P1 and decreases differences of amplitudes for
Na/Pa and Pa/Nb in comparison with the awake state.
Reports on changes of MLAEP latencies and amplitudes
secondary to propofol administration can be found in
adults,14 15 but to the best of our knowledge, such findings
have not been described in children.
Munoz and colleagues16 reported changes in the AEP
index (A-Line ARX, AAI) with propofol in children. However,
the data quality was poor and only 12 out of 20 patients
had reliable data sets. We were able to measure MLAEP for
all our patients at each time-point with a good quality. Fur-
thermore, we observed that MLAEP latencies increased over
time under the influence of propofol. This is in good
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Fig 1 Peak latencies Na, Pa, Nb, and P1 at different conditions; multiple adjusted P-values after closed testing using the Page test and the
Wilcoxon signed-rank test. Symbols for statistical significance: *indicates comparison with the 0 mg ml21 group, #with the 3 mg ml21
group, †with the 6 mg ml21 group, and §with the 9 mg ml21 group. One symbol reflects a P-value of ,0.05, two symbols a P-value of
,0.01, and three symbols a P-value of ,0.001. Owing to the applied measuring system, the upper limit was set at 100 ms; therefore,
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Fig 2 Original MLAEP curves of an 11-yr-old boy.
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Fig 3 Comparison of the peak latency differences Na/Pa, Pa/Nb, and Nb/P1 at different conditions; multiple adjusted P-values after closed
testing using the Page test and the Wilcoxon signed-rank test. Symbols for statistical significance: *indicates comparison with the 0 mg ml21
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accordance with findings in adult patients17 and our earlier
results with sevoflurane in children.8 18 We also observed sig-
nificant changes in the amplitudes of MLAEP. This contrasts
with our previous work, where we did not detect changes
in the latencies of MLAEP with sevoflurane.8 The changes in
MLAEP amplitudes in this current investigation are consistent
with observations in adults in whom a significant decrease in
amplitudes has also been seen.15 17
Our second major finding is that MLAEPs are altered by
propofol in a dose-dependent manner. With increasing
target propofol concentrations, MLAEPs show increasing la-
tencies and decreasing amplitudes. This dose-dependency
of increasing latencies and decreasing amplitudes has also
been reported in several studies in adults.14 19
For our study, we decided to administer propofol via a TCI
pump based on Kataria and colleagues’ model, which is vali-
dated in paediatric patients. In contrast to adults, however,
there are more confounding factors that can affect a TCI
system in paediatric patients. Greater inter-individual phar-
macokinetic variability with respect to age and the matur-
ation process exists in children. TCI pumps deliver a dose
calculated according to a particular pharmacokinetic model
based on specific parameters such as age and weight.20 21
A major drawback of pharmacokinetic models is that esti-
mated concentrations can differ from actual blood concen-
trations. Nevertheless, an increase in target concentrations
invariably leads to an increase in administration rates. In
our study, higher target concentrations, that is, higher
administration rates, were associated with increased MLAEP
latencies and decreased differences in amplitudes.
Since the dose–effect relationship of propofol on MLAEP
cannot be accurately described by using target concentration
alone, we measured venous propofol concentrations. This
revealed a sigmoidal relationship between blood propofol
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Fig 4 MLAEP peak latencies Na, Pa, and Nb in correlation with propofol plasma concentration; sigmoidal dose–response model, curve fitted.
Owing to the applied measuring system, the upper limit was set at 100 ms; therefore, peak latencies Nb and P1 experience an artificial ceiling
effect at propofol concentrations of 6 and 9 mg ml21.
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concentrations and peak latencies. A similar relationship was
demonstrated for amplitudes.
One of the limitations of our study was that blood samples
were not available in all our patients for estimation of venous
propofol concentrations. Nevertheless, the data points dem-
onstrate a sigmoidal dose–effect relationship, as seen in
other studies using alternative monitoring systems, for
example, BIS and A-Line.16 For the peak Nb and P1 latencies,
the limit value of 100 ms was reached when higher propofol
plasma concentrations were achieved. While MLAEP mea-
surements still differed significantly between the TCI groups
of 6 and 9 mg ml21, the measured plasma MLAEP effect rela-
tionship needs to be interpreted cautiously with these trun-
cated data. To eliminate this artificial ceiling effect due to
the limit of 100 ms, we calculated a modified AEP index
based on the algorithm of Kenny and Mantzaridis.11 12 This
index takes into account changes in amplitude and latency,
but does not rely on identification of the positive and negative
peaks of each AEP waveform. The AEP index reduced signifi-
cantly with increasing calculated and measured plasma pro-
pofol concentrations. This AEP index was calculated offline
after the actual MLAEP raw measurement. In contrast to our
study with good signal quality, Munoz and colleagues16
described a poor A-line ARX index (AAI) signal quality under
the influence of propofol in children. The main difference
is—besides the two different methods—the ‘collection time’
of the MLAEP. The AAI system enables the extraction of the
AEP within 1.7 s.22 The system used in the current study gen-
erates one AEP from 1000 sweeps gathered during 108 s. The
advantage of the latter is a higher AEP quality but at the price
of a long duration of acquisition. This may explain the different
findings in these two studies.
Another important fact is that MLAEPs have an age de-
pendency which partially reflects the electrophysiological
correlate of the ongoing maturation processes of central
auditory pathways.8 23 24 MLAEP values are thought to be
comparable with those measured in adults by the age of
12–15 yr.24 25 In the current study, MLAEP could be detected
in all participants regardless of the age of the participant and
the propofol concentrations. Also the MLAEP peak latencies
all increased similarly with higher propofol concentrations,
which is consistent with the findings of Iselin-Chaves and
colleagues17 who investigated MLAEP under the influence
of increasing propofol concentrations.
Additionally, all children were premedicated with midazo-
lam, which could be a confounding factor. Benzodiazepines
are known to influence MLAEP when continuously applied
but very few when given as a single medication.26
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Table 2 Parameter estimated from the Emax model. Measured venous propofol concentrations, peak latencies, and amplitude differences were
fitted to the following Emax model: Effect¼E0+(Emax2E0)×Cplasmag /(Cplasma50g +Cplasmag ). E0, baseline effect; Emax, maximum drug effect; Cplasma,
propofol plasma concentration; Cplasma50, propofol concentration associated with 50% of maximum drug effect; g, Hill coefficient
Peak Na Peak Pa Peak Nb Peak P1 Na/Pa Pa/Nb Nb/P1
Emax 38.99 100 99.6 99.24 0.62 0.00001 0.33
C50 4.377 6.828 4.076 2.197 1.267 3.117 2.841
g 2.108 1.935 2.344 4.082 4.779 1.41 7.06
E0 17.62 36.06 53.64 74.67 2.76 1.643 1.516
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In summary, this studyshowed that propofol anaesthesia in
children increases MLAEP peak latencies Na, Pa, Nb, and P1 and
decreases differences of amplitudes for Na/Pa and Pa/Nb.
In contrast to adults, the peak Pa seems to be the better
readout parameter for alterations in depth of anaesthesia
with propofol. In adult patients, Thornton and colleagues27
evaluated the peak Nb as the best readout parameter. Add-
itionally, our data demonstrated that differences in ampli-
tudes are detectable and show a relationship to increasing
propofol concentrations. Na/Pa seems to have more sensitiv-
ity at lower propofol levels, whereas Pa/Nb has more discrim-
ination at higher propofol levels.
These findings may be important to further investigations
examining MLAEP and indexed MLAEP as a tool for monitor-
ing depth of anaesthesia in children, as we now have a better
insight into the raw MLAEP dynamics in children.
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